Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $20.8333.

A number of equities research analysts have recently issued reports on the stock. Westpark Capital boosted their price target on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 8th. Evercore ISI reduced their price target on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research note on Monday, September 15th. HC Wainwright assumed coverage on shares of Enanta Pharmaceuticals in a research note on Monday, July 28th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Jefferies Financial Group raised shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $14.00 to $20.00 in a research note on Wednesday, October 1st.

Enanta Pharmaceuticals Price Performance

Shares of ENTA stock opened at $10.82 on Tuesday. The firm’s 50-day moving average is $9.74 and its two-hundred day moving average is $7.87. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $15.34. The company has a market capitalization of $231.31 million, a PE ratio of -2.50 and a beta of 0.89.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The company had revenue of $18.31 million for the quarter, compared to the consensus estimate of $16.21 million. Sell-side analysts forecast that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ENTA. Millennium Management LLC grew its holdings in shares of Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after purchasing an additional 449,945 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Enanta Pharmaceuticals by 674.7% in the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after purchasing an additional 311,010 shares in the last quarter. Stonepine Capital Management LLC grew its holdings in shares of Enanta Pharmaceuticals by 78.0% in the first quarter. Stonepine Capital Management LLC now owns 590,742 shares of the biotechnology company’s stock valued at $3,261,000 after purchasing an additional 258,842 shares in the last quarter. Trexquant Investment LP grew its holdings in shares of Enanta Pharmaceuticals by 113.4% in the first quarter. Trexquant Investment LP now owns 290,059 shares of the biotechnology company’s stock valued at $1,601,000 after purchasing an additional 154,105 shares in the last quarter. Finally, PDT Partners LLC grew its holdings in shares of Enanta Pharmaceuticals by 217.5% in the first quarter. PDT Partners LLC now owns 106,200 shares of the biotechnology company’s stock valued at $586,000 after purchasing an additional 72,751 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.